Cardiovascular Interventions and Stroke

Patent Foramen Ovale Closure in Patients With and Without Nickel Hypersensitivity: A Randomized Trial

Circulation: Cardiovascular Interventions

MARCH 9, 2025

Circulation: Cardiovascular Interventions, Ahead of Print. No significant differences were observed in documented arrhythmias, bleeding, or stroke. Background:Nickel-containing devices, such as the Amplatzer PFO Occluder and Gore Cardioform Septal Occluder (GSO), are used for transcatheter patent foramen ovale (PFO) closure.

Chest Pain

Chest Pain Cardiovascular Interventions Document Arrhythmia

Supplementing Randomized Trial Data to Answer a Real World Question: Discharge to Home Status as a Heuristic for Stroke Severity After Transcatheter Aortic Valve Replacement

Circulation: Cardiovascular Interventions

JUNE 4, 2024

Circulation: Cardiovascular Interventions, Ahead of Print.

Aortic valve

Aortic valve Cardiovascular Interventions Circulation Aortic

Clinical Outcomes of Percutaneous Transcatheter Release of Stuck Mechanical Mitral Valve With Cerebral Embolic Protection

Circulation: Cardiovascular Interventions

JUNE 10, 2024

Circulation: Cardiovascular Interventions, Ahead of Print. During the follow-up, 12.50% (n=3) all-cause death, 4.17% (n=1) stroke, and 16.67% (n=4) recurrence were seen. 1273.47) days, stroke was 1211.38 (95% CI, 1110.40–1312.35) The study participants were followed up for a median period of 344.50 (65.00–953.75)

Embolism

Embolism Bicuspid/Mitral Outcomes Cardiovascular Interventions

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Transcarotid Versus Surgical Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis

Circulation: Cardiovascular Interventions

MARCH 26, 2025

Circulation: Cardiovascular Interventions, Ahead of Print. The primary outcome was a composite of death from any cause, stroke/transient ischemic attack, and procedure-related or valve-related hospitalization at 30 days and at 1 year. versus TC-TAVR, 12.7%; hazard ratio, 1.63 [95% CI, 0.982.73]).CONCLUSIONS:TC-TAVR

Aortic valve

Aortic valve Aortic Stenosis TAVR

Use of Claims to Assess Outcomes and Treatment Effects in the Evolut Low Risk Trial

Circulation: Cardiovascular Interventions

JANUARY 20, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 1 , Page e014592, January 1, 2025. There was no difference between treatment arms for the primary end point of death or disabling stroke using trial data (hazard ratio, 0.83 [95% CI, 0.411.68]) or claims data (hazard ratio, 0.89 [95% CI, 0.431.81]; interactionP=0.71).CONCLUSIONS:Claims-based

Aortic valve

Aortic valve Outcomes Pacemaker Aortic

Characteristics and Outcomes of PCI Among Patients Ineligible for Surgical Revascularization in the Veterans Affairs Healthcare System

Circulation: Cardiovascular Interventions

MARCH 17, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 3 , Page e014899, March 1, 2025. BACKGROUND:Ineligibility for surgical revascularization is increasingly prevalent and associated with increased mortality after percutaneous coronary intervention (PCI).

Coronary Artery Disease

Coronary Artery Disease Outcomes Myocardial Infarction Cardiovascular Interventions

Association Between Polyvascular Disease and Transcatheter Aortic Valve Replacement Outcomes: Insights from the STS/ACC TVT Registry

Circulation: Cardiovascular Interventions

OCTOBER 22, 2023

Circulation: Cardiovascular Interventions, Ahead of Print. Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Primary outcome was all-cause mortality. 2VB-PVD, HR 1.12; 95% CI, 1.09-1.15,

Aortic valve

Aortic valve Aortic TAVR Outcomes

Outcomes Following Transcatheter Aortic Valve Replacement for Aortic Stenosis in Patients With Type 0 Bicuspid, Type 1 Bicuspid, and Tricuspid Aortic Valves

Circulation: Cardiovascular Interventions

OCTOBER 17, 2023

Circulation: Cardiovascular Interventions, Ahead of Print. Poverall=0.099) and all stroke (30 days: 1.0% BACKGROUND:Data concerning the outcomes of transcatheter aortic valve replacement in type 0 bicuspid aortic stenosis (AS) are scarce. In the matched population, differences in mortality (30 days: 4.2%

Aortic valve

Aortic valve Bicuspid/Mitral Aortic Tricuspid

Abstract 4142612: External validation of CHIP score in patients undergoing in patients undergoing percutaneous coronary intervention in a large-scale Chinese cohort

Circulation

NOVEMBER 11, 2024

Background:The CHIP score, developed from the BCIS (British Cardiovascular Intervention Society) database, predicts adverse in-hospital MACCE (major adverse cardiovascular and cerebrovascular events). The primary endpoint was 5-year MACCE, defined as a composite of all-cause mortality, myocardial infarction, and stroke.

Myocardial Infarction

Myocardial Infarction Cardiovascular Interventions Stroke Strokes

Avocados for the Heart; Cardiology's Sad State; CBD for Pulmonary Hypertension?

Heart 2023 Conference

APRIL 20, 2022

(Naturopathic Medicine) According to a subanalysis of a randomised study, low-dose edoxaban (Savaysa) was related with a reduced stroke risk and a negligible increase in bleeding in older Afib patients at high bleeding risk. Reconsider your position.

Pulmonary

Pulmonary Hypertension AFIB COVID-19

Percutaneous Left Ventricular Unloading During High-Risk Coronary Intervention: Rationale and Design of the CHIP-BCIS3 Randomized Controlled Trial

Circulation: Cardiovascular Interventions

FEBRUARY 27, 2024

Circulation: Cardiovascular Interventions, Ahead of Print. INTRODUCTION:Percutaneous coronary intervention for complex coronary disease is associated with a high risk of cardiogenic shock. This can cause harm and limit the quality of revascularization achieved, especially when left ventricular function is impaired at the outset.

Cardiogenic Shock

Cardiogenic Shock Myocardial Infarction Coronary Artery Disease Quality of Life

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices

Cardiometabolic Health Congress

JULY 17, 2024

February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes.

Tricuspid

Tricuspid Open-Heart Surgery Kidney Disease Defibrillator

Reaching the Underserved in Rural America

The Beat Blog

MAY 2, 2023

According to the Journal of the American College of Cardiology, cardiovascular disease has nearly doubled in prevalence since 1990, with deaths due to cardiovascular disease increasing by over 50%. 5 These conditions, if detected and addressed early and appropriately, can be treated and prevented. For the Risk Bearing Entity e.g

Atrial Fibrillation

Atrial Fibrillation Cardiovascular Disease Technology Hospital

Lifelong risk of stroke after TAVR: Findings from SwissTAVI Registry

Cardiology Update

FEBRUARY 6, 2024

Stroke stands as a major contributor to global morbidity and mortality, imposing a substantial burden on patients, societies, and healthcare systems worldwide. Within the realm of transcatheter aortic valve replacement (TAVR), stroke emerges as a recognized adverse event, manifesting at various stages during and after the procedure.

TAVR

TAVR Stroke Strokes Aortic valve

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

Published Research

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)

Research

Research Coronary Artery Bypass Graft Aortic valve Congenital

What Cardiometabolic Clinicians Can Be Thankful For This Year

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Advancements in Cardiovascular Interventions and Clinical Guidelines 2024 ESC Guidelines for Chronic Coronary Syndromes : Updated guidelines from the European Society of Cardiology (ESC) emphasized shortened dual antiplatelet therapy (DAPT) durations and the potential for P2Y12 inhibitor monotherapy after percutaneous coronary intervention (PCI).

Blood Pressure

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease

Cardiovascular Update

Patent Foramen Ovale Closure in Patients With and Without Nickel Hypersensitivity: A Randomized Trial

Supplementing Randomized Trial Data to Answer a Real World Question: Discharge to Home Status as a Heuristic for Stroke Severity After Transcatheter Aortic Valve Replacement

Clinical Outcomes of Percutaneous Transcatheter Release of Stuck Mechanical Mitral Valve With Cerebral Embolic Protection

Webinars

Transcarotid Versus Surgical Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis

Use of Claims to Assess Outcomes and Treatment Effects in the Evolut Low Risk Trial

Characteristics and Outcomes of PCI Among Patients Ineligible for Surgical Revascularization in the Veterans Affairs Healthcare System

Association Between Polyvascular Disease and Transcatheter Aortic Valve Replacement Outcomes: Insights from the STS/ACC TVT Registry

Outcomes Following Transcatheter Aortic Valve Replacement for Aortic Stenosis in Patients With Type 0 Bicuspid, Type 1 Bicuspid, and Tricuspid Aortic Valves

Abstract 4142612: External validation of CHIP score in patients undergoing in patients undergoing percutaneous coronary intervention in a large-scale Chinese cohort

Avocados for the Heart; Cardiology's Sad State; CBD for Pulmonary Hypertension?

Percutaneous Left Ventricular Unloading During High-Risk Coronary Intervention: Rationale and Design of the CHIP-BCIS3 Randomized Controlled Trial

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices

Reaching the Underserved in Rural America

Lifelong risk of stroke after TAVR: Findings from SwissTAVI Registry

Published Research

Published Research

What Cardiometabolic Clinicians Can Be Thankful For This Year

Stay Connected